Comparison of NEDA3 at one year between alemtuzumab and natalizumab in treatment-naive relapsing-remitting multiple sclerosis patients.

被引：0
|
作者：
Gomez, A. [1 ]
Rodriguez, F. [1 ]
Chico, J. L. [1 ]
Sanchez Sanchez, A. [1 ]
Natera, E. [1 ]
Sainz de la Maza, S. [1 ]
Villar Guimerans, L. M. [2 ]
Buisan Catevilla, F. J. [1 ]
Costa-Frossard Franca, L. [1 ]
Masjuan, J. [1 ]
Monreal, E. [1 ]
机构：
[1] Hosp Ramon & Cajal, Neurol, Madrid, Spain
[2] Hosp Univ Ramon y Cajal, Inmunol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1245
引用
收藏
页码：493 / 493
页数：1
相关论文
共 50 条
  • [31] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [32] Influence of Alemtuzumab Treatment on Peripheral Mediators of Inflammation in Relapsing-Remitting Multiple Sclerosis Patients
    Studer, Valeria
    Ferri, Anna
    Perugini, Jacopo
    Clerici, Valentina Torri
    Confalonieri, Paolo
    Antozzi, Carlo
    Mantegazza, Renato
    Schilke, Edoardo
    Brambilla, Laura
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 25 - 26
  • [33] Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanisms
    Oreja-Guevara, C.
    Ramos Cejudo, J.
    Stark, L.
    Martin Ibanez, N.
    Rodriguez de Antonio, L.
    Chamorro, B.
    Diez-Tejedor, E.
    JOURNAL OF NEUROLOGY, 2011, 258 : 255 - 256
  • [34] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [35] Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis
    Graves, Jennifer
    Galetta, Steven L.
    Palmer, Jeffrey
    Margolin, David H.
    Rizzo, Marco
    Bilbruck, John
    Balcer, Laura J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1302 - 1309
  • [36] Autologous T-Cell Immunotherapy (Tovaxin®) in Treatment-Naive Patients with Active Relapsing-Remitting Multiple Sclerosis
    Markowitz, Clyde
    Wynn, Daniel
    Fox, Edward
    Cohan, Stanley
    McGuire, Dawn
    NEUROLOGY, 2011, 76 (09) : A611 - A612
  • [37] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
  • [38] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [39] Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive Patients
    Coles, Alasdair
    Brinar, Vesna
    Arnold, Douglas
    Cohen, Jeffrey
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Giovannoni, Gavin
    Stojanovic, Miroslav
    Lake, Stephen
    Margolin, David
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2012, 78
  • [40] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
12345